Danaher Corporation $DHR Shares Sold by First National Trust Co

First National Trust Co decreased its position in Danaher Corporation (NYSE:DHR) by 2.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 15,719 shares of the conglomerate’s stock after selling 458 shares during the quarter. First National Trust Co’s holdings in Danaher were worth $3,105,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Vanguard Group Inc. raised its position in shares of Danaher by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate’s stock worth $12,296,123,000 after acquiring an additional 230,966 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Danaher by 3.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate’s stock worth $4,016,404,000 after acquiring an additional 612,154 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Danaher by 2.3% during the 1st quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate’s stock worth $1,800,614,000 after acquiring an additional 194,466 shares in the last quarter. Invesco Ltd. raised its position in shares of Danaher by 44.5% during the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock worth $965,259,000 after acquiring an additional 1,450,703 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Danaher by 4.0% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 4,230,087 shares of the conglomerate’s stock worth $867,168,000 after acquiring an additional 163,332 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Trading Down 1.9%

Shares of DHR stock opened at $216.89 on Wednesday. The business’s 50 day moving average is $203.06 and its two-hundred day moving average is $199.03. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $258.23. The company has a market capitalization of $153.20 billion, a P/E ratio of 44.72, a price-to-earnings-growth ratio of 3.39 and a beta of 0.77. The company has a current ratio of 1.52, a quick ratio of 1.10 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, October 21st. The conglomerate reported $1.89 earnings per share for the quarter, beating the consensus estimate of $1.72 by $0.17. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The company had revenue of $6.05 billion for the quarter, compared to the consensus estimate of $6 billion. During the same period last year, the business posted $1.71 EPS. The company’s revenue was up 4.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Equities analysts forecast that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be paid a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, September 26th. Danaher’s dividend payout ratio (DPR) is 26.39%.

Insider Buying and Selling at Danaher

In other Danaher news, Director Teri List sold 2,778 shares of Danaher stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the transaction, the director directly owned 20,751 shares in the company, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 11.20% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. UBS Group cut their target price on Danaher from $240.00 to $225.00 and set a “buy” rating on the stock in a research report on Wednesday, July 23rd. TD Cowen raised their price target on Danaher from $250.00 to $260.00 and gave the stock a “buy” rating in a research note on Wednesday, October 22nd. Rothschild & Co Redburn restated a “neutral” rating and set a $220.00 price target (down previously from $245.00) on shares of Danaher in a research note on Wednesday, October 8th. Robert W. Baird set a $247.00 price target on Danaher in a research note on Wednesday, October 22nd. Finally, Rothschild Redb downgraded Danaher from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 8th. Eighteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $243.39.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.